Genzyme Corp., which is based in Cambridge and has significant operations MetroWest, announced that it and Bayer had been granted a supplemental biologics license by the U.S. Food and Drug Administration for the Campath B-cell chronic lymphocytic leukemia drug.
The FDA also granted single-agent Campath regular approval for the treatment of CLL.
Campath was originally approved by the FDA in 2001 under accelerated approval regulations.Â
